Trial Profile
A Phase I Study on Dendritic Cells Loaded With Allogeneous Cell Lysate in Patients With Mesothelioma as Maintenance Treatment After Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Autologous dendritic cell vaccine Amphera (Primary) ; Autologous dendritic cell vaccine Amphera (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- 08 Jun 2021 Results of a pooled analysis assessing the long-term survival of the patients treated with dendritic cell in these three phase 1 studies presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 23 May 2016 New trial record